Natera, Inc. (NASDAQ:NTRA) CEO Sells $725,895.32 in Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 6,779 shares of Natera stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $107.08, for a total value of $725,895.32. Following the completion of the transaction, the chief executive officer now directly owns 219,456 shares of the company's stock, valued at $23,499,348.48. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, April 29th, Steven Leonard Chapman sold 4,084 shares of Natera stock. The shares were sold at an average price of $93.14, for a total value of $380,383.76.
• On Tuesday, April 23rd, Steven Leonard Chapman sold 2,552 shares of Natera stock. The shares were sold at an average price of $91.38, for a total value of $233,201.76.
• On Monday, April 15th, Steven Leonard Chapman sold 6,816 shares of Natera stock. The shares were sold at an average price of $93.13, for a total value of $634,774.08.
• On Thursday, March 28th, Steven Leonard Chapman sold 2,662 shares of Natera stock. The shares were sold at an average price of $90.42, for a total value of $240,698.04.
• On Friday, March 15th, Steven Leonard Chapman sold 83,223 shares of Natera stock. The stock was sold at an average price of $88.96, for a total value of $7,403,518.08.
• On Tuesday, March 5th, Steven Leonard Chapman sold 9,326 shares of Natera stock. The stock was sold at an average price of $88.36, for a total value of $824,045.36.

Natera Trading Down 1.9 %

Shares of NASDAQ NTRA traded down $2.04 during trading on Friday, reaching $106.46. The company had a trading volume of 938,873 shares, compared to its average volume of 1,435,483. The company's fifty day moving average price is $93.96 and its 200-day moving average price is $73.60. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $108.75. The stock has a market cap of $13.07 billion, a P/E ratio of -34.12 and a beta of 1.38. The company has a quick ratio of 3.96, a current ratio of 4.12 and a debt-to-equity ratio of 0.36.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.56) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.16. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The firm had revenue of $367.70 million for the quarter, compared to analyst estimates of $316.31 million. During the same quarter in the previous year, the company posted ($1.23) EPS. The business's revenue was up 52.1% on a year-over-year basis. As a group, research analysts expect that Natera, Inc. will post -2.43 earnings per share for the current year.

Institutional Investors Weigh In On Natera

A number of institutional investors have recently made changes to their positions in NTRA. Norges Bank bought a new stake in shares of Natera during the 4th quarter valued at about $83,970,000. American Century Companies Inc. boosted its position in shares of Natera by 115.7% during the 3rd quarter. American Century Companies Inc. now owns 1,654,303 shares of the medical research company's stock valued at $73,203,000 after purchasing an additional 887,409 shares in the last quarter. Invesco Ltd. boosted its position in shares of Natera by 52.0% during the 3rd quarter. Invesco Ltd. now owns 2,529,496 shares of the medical research company's stock valued at $111,930,000 after purchasing an additional 865,404 shares in the last quarter. Perceptive Advisors LLC boosted its position in shares of Natera by 289.7% during the 4th quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company's stock valued at $53,258,000 after purchasing an additional 632,047 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Natera by 5.7% during the 4th quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company's stock worth $687,280,000 after buying an additional 588,147 shares during the period. Institutional investors own 99.90% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently commented on NTRA. Piper Sandler boosted their price target on Natera from $110.00 to $120.00 and gave the stock an "overweight" rating in a report on Tuesday. TD Cowen boosted their price target on Natera from $123.00 to $137.00 and gave the stock a "buy" rating in a report on Friday, May 10th. Craig Hallum began coverage on Natera in a report on Monday, April 8th. They set a "buy" rating and a $117.00 price target for the company. Raymond James cut Natera from a "strong-buy" rating to an "outperform" rating and boosted their price target for the stock from $68.00 to $85.00 in a report on Tuesday, February 20th. Finally, Robert W. Baird boosted their price objective on Natera from $99.00 to $117.00 and gave the stock an "outperform" rating in a research report on Friday, May 10th. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $98.47.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.